S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:ATRC

AtriCure Stock Forecast, Price & News

$71.08
+3.49 (+5.16%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$68.14
$71.88
50-Day Range
$63.40
$87.14
52-Week Range
$44.85
$89.18
Volume
250,800 shs
Average Volume
305,178 shs
Market Capitalization
$3.26 billion
P/E Ratio
74.82
Dividend Yield
N/A
Beta
1.14
30 days | 90 days | 365 days | Advanced Chart
Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.


AtriCure logo

About AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
750
Year Founded
2000

Sales & Book Value

Annual Sales
$206.53 million
Book Value
$10.64 per share

Profitability

Net Income
$-48.15 million
Pretax Margin
17.62%

Debt

Price-To-Earnings

Miscellaneous

Free Float
43,268,000
Market Cap
$3.26 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

Social Links


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

291st out of 1,394 stocks

Surgical & Medical Instruments Industry

30th out of 126 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












AtriCure (NASDAQ:ATRC) Frequently Asked Questions

Is AtriCure a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure
or view top-rated stocks.

How has AtriCure's stock price been impacted by Coronavirus (COVID-19)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 101.5% and is now trading at $71.08.
View which stocks have been most impacted by COVID-19
.

Are investors shorting AtriCure?

AtriCure saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 693,900 shares, a decrease of 26.0% from the October 31st total of 937,400 shares. Based on an average daily trading volume, of 188,700 shares, the days-to-cover ratio is presently 3.7 days. Approximately 1.6% of the shares of the stock are short sold.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for AtriCure
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Wednesday, November, 3rd. The medical device company reported $2.11 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $2.39. The medical device company earned $70.46 million during the quarter, compared to analysts' expectations of $68.95 million. AtriCure had a negative trailing twelve-month return on equity of 11.12% and a net margin of 17.53%. During the same period in the previous year, the firm earned ($0.11) earnings per share.
View AtriCure's earnings history
.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share guidance of $-1.200-$-1.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $-1.350. The company issued revenue guidance of $270 million-$275 million, compared to the consensus revenue estimate of $272.94 million.

What price target have analysts set for ATRC?

8 equities research analysts have issued 12-month target prices for AtriCure's shares. Their forecasts range from $75.00 to $120.00. On average, they expect AtriCure's share price to reach $90.50 in the next year. This suggests a possible upside of 27.3% from the stock's current price.
View analysts' price targets for AtriCure
or view top-rated stocks among Wall Street analysts.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.95%), Alliancebernstein L.P. (6.34%), Invesco Ltd. (4.95%), Credit Suisse AG (2.48%), Macquarie Group Ltd. (2.38%) and TimesSquare Capital Management LLC (2.07%). Company insiders that own AtriCure stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends for AtriCure
.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Wellington Management Group LLP, TimesSquare Capital Management LLC, Emerald Advisers LLC, Morgan Stanley, Pura Vida Investments LLC, Principal Financial Group Inc., and Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin, and Vinayak Doraiswamy.
View insider buying and selling activity for AtriCure
or view top insider-selling stocks.

Which institutional investors are buying AtriCure stock?

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Balyasny Asset Management LLC, Polar Capital Holdings Plc, Assenagon Asset Management S.A., CastleArk Alternatives LLC, Dimensional Fund Advisors LP, Alliancebernstein L.P., and Macquarie Group Ltd.. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure
or or view top insider-buying stocks.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $71.08.

How much money does AtriCure make?

AtriCure has a market capitalization of $3.26 billion and generates $206.53 million in revenue each year. The medical device company earns $-48.15 million in net income (profit) each year or $0.95 on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 750 workers across the globe.

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART.

When was AtriCure founded?

AtriCure was founded in 2000.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

Where are AtriCure's headquarters?

AtriCure is headquartered at 7555 INNOVATION WAY, MASON OH, 45040.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at (513) 755-4100 or via fax at 513-755-4567.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.